Related references
Note: Only part of the references are listed.Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
Sreenath M. Krishnan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Carlos Zamora Atenza et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Pharmacometrics Golems: Exposure-Response Models in Oncology
Akash Khandelwal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
Yulia Vugmeyster et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Toward Project Optimus for Oncology Precision Medicine: Multi-Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology
Karthik Venkatakrishnan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
Sarah Goring et al.
LUNG CANCER (2022)
Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure-response relationships for large-molecule oncology drugs
Victor Poon et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel
Sreenath M. Krishnan et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis
Yangyun Huang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
A multistate model for early decision-making in oncology
Ulrich Beyer et al.
BIOMETRICAL JOURNAL (2020)
Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review
Antoine Petitcollin et al.
CLINICAL PHARMACOKINETICS (2020)
Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1
Yulia Vugmeyster et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Haiqing Isaac Dai et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
Justin J. Wilkins et al.
ADVANCES IN THERAPY (2019)
Are 90% of deaths from cancer caused by metastases?
Hanna Dillekas et al.
CANCER MEDICINE (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
Justin J. Wilkins et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
David C. Turner et al.
CLINICAL CANCER RESEARCH (2018)
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
Paul G. Baverel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
Hongshan Li et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis
C. Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma
X. Wang et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
Anne-Gaelle Dosne et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia et al.
ONCOTARGET (2016)
Understanding cachexia as a cancer metabolism syndrome
P. E. Porporato
ONCOGENESIS (2016)
Emerging markers of cachexia predict survival in cancer patients
Patrizia Mondello et al.
BMC CANCER (2014)
Gompertz-Makeham life expectancies: Expressions and applications
Trifon I. Missov et al.
THEORETICAL POPULATION BIOLOGY (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multi-state models for the analysis of time-to-event data
Luis Meira-Machado et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2009)